Detalles de la búsqueda
1.
Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.
Rheumatology (Oxford)
; 62(2): 606-616, 2023 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35766811
2.
Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
Lancet
; 395(10230): 1126-1136, 2020 04 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32178766
3.
Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Lancet
; 395(10230): 1115-1125, 2020 04 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-32178765
4.
Resolution of enthesitis by guselkumab and relationships to disease burden: 1-year results of two phase 3 psoriatic arthritis studies.
Rheumatology (Oxford)
; 60(11): 5337-5350, 2021 11 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33822898
5.
Sirukumab for rheumatoid arthritis: the phase III SIRROUND-D study.
Ann Rheum Dis
; 76(12): 2001-2008, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28855173
6.
Sirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapy.
Ann Rheum Dis
; 73(9): 1616-25, 2014 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-24699939
7.
Radiographic benefit and maintenance of clinical benefit with intravenous golimumab therapy in patients with active rheumatoid arthritis despite methotrexate therapy: results up to 1 year of the phase 3, randomised, multicentre, double blind, placebo controlled GO-FURTHER trial.
Ann Rheum Dis
; 73(12): 2152-9, 2014 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24001888
8.
Association between enthesitis/dactylitis resolution and patient-reported outcomes in guselkumab-treated patients with psoriatic arthritis.
Clin Rheumatol
; 43(5): 1591-1604, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38472528
9.
Guselkumab plus golimumab combination therapy versus guselkumab or golimumab monotherapy in patients with ulcerative colitis (VEGA): a randomised, double-blind, controlled, phase 2, proof-of-concept trial.
Lancet Gastroenterol Hepatol
; 8(4): 307-320, 2023 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-36738762
10.
Low rates of radiographic progression associated with clinical efficacy following up to 2 years of treatment with guselkumab: results from a phase 3, randomised, double-blind, placebo-controlled study of biologic-naïve patients with active psoriatic arthritis.
RMD Open
; 9(1)2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36828643
11.
Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study.
ACR Open Rheumatol
; 5(3): 149-164, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-36762512
12.
Safety of Guselkumab With and Without Prior Tumor Necrosis Factor Inhibitor Treatment: Pooled Results Across 4 Studies in Patients With Psoriatic Arthritis.
J Rheumatol
; 50(6): 769-780, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-36642439
13.
Guselkumab, a Selective Interleukin-23 p19 Subunit Inhibitor, Resolves Dactylitis in Patients With Active Psoriatic Arthritis: Pooled Results Through Week 52 From Two Phase 3 Studies.
ACR Open Rheumatol
; 5(4): 227-240, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-36880890
14.
Meaningful Improvement in General Health Outcomes with Guselkumab Treatment for Psoriatic Arthritis: Patient-Reported Outcomes Measurement Information System-29 Results from a Phase 3 Study.
Patient
; 15(6): 657-668, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-35768650
15.
Long-Term Efficacy and Safety of Guselkumab, a Monoclonal Antibody Specific to the p19 Subunit of Interleukin-23, Through Two Years: Results From a Phase III, Randomized, Double-Blind, Placebo-Controlled Study Conducted in Biologic-Naive Patients With Active Psoriatic Arthritis.
Arthritis Rheumatol
; 74(3): 475-485, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34719872
16.
Sustained and improved guselkumab response in patients with active psoriatic arthritis regardless of baseline demographic and disease characteristics: pooled results through week 52 of two phase III, randomised, placebo-controlled studies.
RMD Open
; 8(1)2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35296534
17.
Efficacy and Safety of Guselkumab, an Interleukin-23p19-Specific Monoclonal Antibody, Through One Year in Biologic-Naive Patients With Psoriatic Arthritis.
Arthritis Rheumatol
; 73(4): 604-616, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33043600
18.
Pooled Safety Results Through 1 Year of 2 Phase III Trials of Guselkumab in Patients With Psoriatic Arthritis.
J Rheumatol
; 48(12): 1815-1823, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33934076
19.
Efficacy of guselkumab on axial involvement in patients with active psoriatic arthritis and sacroiliitis: a post-hoc analysis of the phase 3 DISCOVER-1 and DISCOVER-2 studies.
Lancet Rheumatol
; 3(10): e715-e723, 2021 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-38287608
20.
Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-naïve or TNFα inhibitor-experienced.
RMD Open
; 7(1)2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33568556